| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Molecular Pathology and 2 Gastroenterological Surgery, Tohoku University School of Medicine, Sendai Miyagi, Japan and 3 Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Requests for reprints: Akira Horii, Department of Molecular Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. Phone: 81-22-717-8042; Fax: 81-22-717-8047; E-mail: horii{at}mail.tains.tohoku.ac.jp.
AURKA/STK15/BTAK, the gene encoding Aurora A kinase that is involved in the regulation of centrosomes and segregation of chromosomes, is frequently amplified and overexpressed in various kinds of human cancers, including pancreatic cancer. To address its possibility as a therapeutic target for pancreatic cancer, we employed the RNA interference technique to knockdown AURKA expression and analyzed its phenotypes. We found that the specific knockdown of AURKA in cultured pancreatic cancer cells strongly suppressed in vitro cell growth and in vivo tumorigenicity. The knockdown induced the accumulation of cells in the G2-M phase and eventual apoptosis. Furthermore, we observed a synergistic enhancement of the cytotoxicity of taxanes, a group of chemotherapeutic agents impairing G2-M transition, by the RNA interferencemediated knockdown of AURKA. These results indicate that inhibition of AURKA expression can result in potent antitumor activity and chemosensitizing activity to taxanes in human pancreatic cancer.
Key Words: aurora A pancreatic cancer RNAi taxane
This article has been cited by other articles:
![]() |
H. H. Lee, Y. Zhu, K. M Govindasamy, and G. Gopalan Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells Endocr. Relat. Cancer, September 1, 2008; 15(3): 765 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth Clin. Cancer Res., September 1, 2008; 14(17): 5437 - 5446. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.-G. Delcros, M. Toller, F. Curcio, F. S Ambesi-Impiombato, M. D'Armiento, and S. Ulisse Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines Endocr. Relat. Cancer, June 1, 2008; 15(2): 559 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Man, J. Rosa, Y. L. Yip, A. L.-M. Cheung, Y. L. Kwong, S. J. Doxsey, and S. W. Tsao Id1 Overexpression Induces Tetraploidization and Multiple Abnormal Mitotic Phenotypes by Modulating Aurora A Mol. Biol. Cell, June 1, 2008; 19(6): 2389 - 2401. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Gautschi, J. Heighway, P. C. Mack, P. R. Purnell, P. N. Lara Jr., and D. R. Gandara Aurora Kinases as Anticancer Drug Targets Clin. Cancer Res., March 15, 2008; 14(6): 1639 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia Blood, March 1, 2008; 111(5): 2854 - 2865. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wang, L. Liu, and R. D. Brinton Estradiol-17 -Induced Human Neural Progenitor Cell Proliferation Is Mediated by an Estrogen Receptor -Phosphorylated Extracellularly Regulated Kinase Pathway Endocrinology, January 1, 2008; 149(1): 208 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lassmann, Y. Shen, U. Jutting, P. Wiehle, A. Walch, G. Gitsch, A. Hasenburg, and M. Werner Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy Clin. Cancer Res., July 15, 2007; 13(14): 4083 - 4091. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Landen Jr., Y. G. Lin, A. Immaneni, M. T. Deavers, W. M. Merritt, W. A. Spannuth, D. C. Bodurka, D. M. Gershenson, W. R. Brinkley, and A. K. Sood Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients Clin. Cancer Res., July 15, 2007; 13(14): 4098 - 4104. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. LeRoy, J. J. Hunter, K. M. Hoar, K. E. Burke, V. Shinde, J. Ruan, D. Bowman, K. Galvin, and J. A. Ecsedy Localization of Human TACC3 to Mitotic Spindles Is Mediated by Phosphorylation on Ser558 by Aurora A: A Novel Pharmacodynamic Method for Measuring Aurora A Activity Cancer Res., June 1, 2007; 67(11): 5362 - 5370. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shi, T. Reiman, W. Li, C. A. Maxwell, S. Sen, L. Pilarski, T. R. Daniels, M. L. Penichet, R. Feldman, and A. Lichtenstein Targeting aurora kinases as therapy in multiple myeloma Blood, May 1, 2007; 109(9): 3915 - 3921. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, S. K. Balani, O. Burenkova, W. Chen, K. M. Galvin, K. M. Hoar, J. J. Huck, P. J. LeRoy, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase PNAS, March 6, 2007; 104(10): 4106 - 4111. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tanaka, Y. Hashimoto, T. Ito, K. Kondo, M. Higashiyama, S. Tsunoda, C. Ortiz, Y. Sakai, J. Inazawa, and Y. Shimada The Suppression of Aurora-A/STK15/BTAK Expression Enhances Chemosensitivity to Docetaxel in Human Esophageal Squamous Cell Carcinoma Clin. Cancer Res., February 15, 2007; 13(4): 1331 - 1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fu, M. Bian, Q. Jiang, and C. Zhang Roles of Aurora Kinases in Mitosis and Tumorigenesis Mol. Cancer Res., January 1, 2007; 5(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Bartz, Z. Zhang, J. Burchard, M. Imakura, M. Martin, A. Palmieri, R. Needham, J. Guo, M. Gordon, N. Chung, et al. Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions Mol. Cell. Biol., December 15, 2006; 26(24): 9377 - 9386. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Carvajal, A. Tse, and G. K. Schwartz Aurora Kinases: New Targets for Cancer Therapy Clin. Cancer Res., December 1, 2006; 12(23): 6869 - 6875. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Warner, R. M. Munoz, P. Stafford, E. Koller, L. H. Hurley, D. D. Von Hoff, and H. Han Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol. Cancer Ther., October 1, 2006; 5(10): 2450 - 2458. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Grandis Prognostic Biomarkers in Head and Neck Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5005 - 5006. [Full Text] [PDF] |
||||
![]() |
R. Reiter, P. Gais, U. Jutting, M. K. Steuer-Vogt, A. Pickhard, K. Bink, S. Rauser, S. Lassmann, H. Hofler, M. Werner, et al. Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2006; 12(17): 5136 - 5141. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shi, M. Zou, K. Collison, E. Y. Baitei, Z. Al-Makhalafi, N. R. Farid, and F. A. Al-Mohanna Ribonucleic Acid Interference Targeting S100A4 (Mts1) Suppresses Tumor Growth and Metastasis of Anaplastic Thyroid Carcinoma in a Mouse Model J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2373 - 2379. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lopez-Rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno, K. Wakahara, P. B. Illei, S. Hussain, L. Krug, M. F. Zakowski, et al. Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Res., March 15, 2006; 66(6): 2970 - 2979. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohuchida, K. Mizumoto, N. Ishikawa, K. Fujii, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka The Role of S100A6 in Pancreatic Cancer Development and Its Clinical Implication as a Diagnostic Marker and Therapeutic Target Clin. Cancer Res., November 1, 2005; 11(21): 7785 - 7793. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |